Original Investigation

Perioperative Camrelizumab Plus Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

JAMA Oncology 10.1001/jamaoncol.2026.4642

November 12, 2026 at 11:00 AM EST

Read the full article

In this phase 2 randomized clinical trial, perioperative camrelizumab plus chemotherapy significantly improved EFS with manageable toxic effects, supporting evaluation of intensified perioperative immune priming in resectable HNSCC.

Corresponding Author: Yue He, MD, PhD, Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, 639 Zhizaoju Rd, Shanghai 200011, China (yuehe@sjtu.edu.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.4642

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks